In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged ...

Eli Lilly stock recently achieved a significant milestone, reaching a 52-week high of $935.68, with shares now trading at $935.97. This marks a notable achievement for the pharmaceutical giant, ...

In a bid to boost oral medicine manufacturing capacity in Europe for patients worldwide, Lilly has confirmed plans to invest ...

Investors seeking momentum may have iShares U.S. Pharmaceuticals ETF IHE on radar now. The fund recently hit a new 52-week high. Shares of IHE are up approximately 29.6% from their 52-week low of $58.

Comments from medicines firm Eli Lilly will be a blow to British officials, who are in advanced negotiations with the Trump ...

Market observers are closely monitoring potential developments in discussions between Eli Lilly and the Trump administration. Reports indicate the company may be nearing a landmark agreement that ...

"The UK's inability to retain economic benefits of its R&D is a fatal flaw to any growth strategy," according to the document ...

Eli Lilly, the American pharmaceutical giant, has made two significant announcements that could substantially impact its market position and future growth tr ...

Eli Lilly (LLY) has asked European nations to discard clawback taxes on drug sales, Hannah Kuchler of The Financial Times ...

Heineken’s Harold van den Broek said beer demand remains soft, Tesla’s Vaibhav Taneja flagged tariff drag, Brian Dykes talked ...

Lake City Bank is pleased to announce that Trenton H. Cooper has been promoted to Assistant Vice President, Commercial ...